Inactive Instrument

SenzaGen AB Stock Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for SenzaGen AB
Sales 2024 * 67.55M 6.21M Sales 2025 * 91.65M 8.43M Capitalization 150M 13.79M
Net income 2024 * -15M -1.38M Net income 2025 * -4M -368K EV / Sales 2024 * 2.1 x
Net cash position 2024 * 8M 735K Net cash position 2025 * 9M 827K EV / Sales 2025 * 1.54 x
P/E ratio 2024 *
-10 x
P/E ratio 2025 *
-36.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 61.56%
More Fundamentals * Assessed data

Latest transcript on SenzaGen AB

Managers TitleAgeSince
Chief Executive Officer 50 17-12-31
Director of Finance/CFO 63 16-10-31
Chief Tech/Sci/R&D Officer 42 13-12-31
Members of the board TitleAgeSince
Founder 76 10-08-17
Director/Board Member 59 14-10-14
Director/Board Member 62 19-12-31
More insiders
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Calendar
More about the company